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Abstract 
Background: Higher body-mass index (BMI) is a risk factor for cardiometabolic disease, 
although the underlying causal associations remain unclear. The conflicting evidence with 
respect to the magnitude of association between BMI and cardiometabolic diseases lends 
support to adopting a Mendelian randomisation approach: we aimed to contribute a fairly large 
amount of data with detailed covariate information to this question.  
Methods: The UK Biobank is a prospective general cohort study of adults aged 40–70 years at 
baseline (between 2006 and 2010). We examined 119 859 UK Biobank participants with 
complete cross-sectional phenotypic and genetic data, using a polygenic risk score consisting of 
93 single nucleotide polymorphisms associated with BMI from previous genome-wide 
association studies. We used the polygenic risk score to derive causal estimates using a 
Mendelian randomisation approach. Cardiometabolic outcomes were based on self-report of 
clinical diagnosis for each of hypertension, coronary heart disease, type 2 diabetes, and blood 
pressure. This study was conducted under generic approval from the NHS National Research 
Ethics Service (ref 11/NW/0382).  
Findings: Mendelian randomisation analysis showed significant positive associations (all p 
values <0.0001) between genetically instrumented higher BMI and risk of hypertension (odds 
ratio per 1 SD increase in BMI 1.64, 95% CI 1.48–1.83), coronary heart disease (1.35, 1.09–
1.69), type 2 diabetes (2.53, 2.04–3.13), diastolic blood pressure (difference per 1 SD increase in 
BMI [β] 1.65 mmHg, 0.78–2.52) and systolic blood pressure (1.37, 0.88–1.85). These 
associations were independent of age, sex, Townsend deprivation scores, alcohol intake, and 
smoking history.  
Interpretation: The results of this study add to the evidence of a causal association between 
higher BMI and increased risk of cardiometabolic diseases. This finding has relevance for public 
health policies in countries struggling with increasing obesity levels. BMI is a modifiable risk 
factor for ameliorating risk of cardiometabolic disease. This report advances the field by 
including a fairly large sample size including detailed covariates; by using a 93-locus polygenic 
risk score; and by conducting Mendelian randomisation of BMI on a range of cardiometabolic 
disease outcomes. 
Funding: None. 
